The estimated Net Worth of Arturo Md Molina is at least $1.08 Millón dollars as of 15 November 2023. Arturo Molina owns over 1,848 units of Sutro Biopharma Inc stock worth over $103,849 and over the last 6 years he sold STRO stock worth over $30,012. In addition, he makes $947,360 as Chief Medical Officer at Sutro Biopharma Inc.
Sign up
Arturo Molina STRO stock SEC Form 4 insiders trading
Arturo has made over 8 trades of the Sutro Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,848 units of STRO stock worth $30,012 on 15 November 2023.
The largest trade he's ever made was exercising 12,500 units of Sutro Biopharma Inc stock on 4 March 2022 worth over $57,625. On average, Arturo trades about 3,174 units every 84 days since 2018. As of 15 November 2023 he still owns at least 22,527 units of Sutro Biopharma Inc stock.
You can see the complete history of Arturo Molina stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Arturo Molina biography
Dr. Arturo Molina, M.D. M.S. FACP, is Chief Medical Officer of the Company. From February 2013 to February 2016, Dr. Molina served as Vice President of Oncology Scientific Innovation at Johnson & Johnson’s California Innovation Center, an organization focused on building early stage collaborations with emerging companies. Previously, Dr. Molina served as Chief Medical Officer and Vice President of Clinical Development for Johnson and Johnson’s Ortho Biotech Oncology Research and Development, a unit of Cougar Biotechnology, Inc., Chief Medical Officer of Cougar Biotechnology, Inc., Senior Director and Interim Head of Oncology/Hematology in the Department of Medical Research and Clinical Development at Biogen Idec, Inc., and Senior Director of Medical Affairs at IDEC Pharmaceuticals Corporation. Since 2006, Dr. Molina has served as a National Advisory Committee Member for the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. From 1991 to 2002, Dr. Molina was a faculty staff physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center and Adjunct Professor from 2004 to 2007. Dr. Molina was also on the Board of Directors of the City of Hope Medical Group. Dr. Molina received a B.S. in Zoology and B.A. in Psychology from the University of Texas at Austin and an M.S. in Physiology and M.D. from Stanford University School of Medicine. He is board certified in internal medicine and medical oncology, has an active California medical license and is a staff physician (volunteer) in the Oncology Clinic at the Veterans Affairs Palo Alto Health Care System. Since January 2019, Dr. Molina has been an Adjunct Clinical Associate Professor (volunteer) in the Department of Medicine, Division of Oncology, Stanford University School of Medicine.
What is the salary of Arturo Molina?
As the Chief Medical Officer of Sutro Biopharma Inc, the total compensation of Arturo Molina at Sutro Biopharma Inc is $947,360. There are 3 executives at Sutro Biopharma Inc getting paid more, with William Newell having the highest compensation of $3,817,120.
How old is Arturo Molina?
Arturo Molina is 61, he's been the Chief Medical Officer of Sutro Biopharma Inc since 2016. There are 16 older and 3 younger executives at Sutro Biopharma Inc. The oldest executive at Sutro Biopharma Inc is Dr. Shabbir T. Anik, 68, who is the Chief Technical Operations Officer.
What's Arturo Molina's mailing address?
Arturo's mailing address filed with the SEC is C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160.
Insiders trading at Sutro Biopharma Inc
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund y Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
What does Sutro Biopharma Inc do?
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
What does Sutro Biopharma Inc's logo look like?
Complete history of Arturo Molina stock trades at Protagonist Therapeutics Inc, Sutro Biopharma Inc y Forma Therapeutics
Sutro Biopharma Inc executives and stock owners
Sutro Biopharma Inc executives and other stock owners filed with the SEC include:
-
William Newell,
Chief Executive Officer, Director -
William J. Newell J.D.,
CEO & Director -
Trevor Hallam,
Chief Scientific Officer -
Arturo Molina,
Chief Medical Officer -
William J. Newell,
CEO & Director -
Jane Chung R.Ph.,
Chief Commercial Officer -
Dr. Trevor J. Hallam,
Pres of Research & Chief Scientific Officer -
Linda A. Fitzpatrick,
Chief People & Communications Officer -
Connie Matsui,
Chairman of the Board -
Shalini Sharp,
Independent Director -
Joseph Lobacki,
Independent Director -
Michael Dybbs,
Independent Director -
John Freund,
Independent Director -
Daniel Petree,
Director -
Annie Chang,
Head of Investor Relations -
Diana Landa,
Vice President of Regulatory Affairs -
James Panek,
Director -
Shabbir Anik,
Chief Technical Operations Officer -
Brunilda Shtylla,
Vice President - Business Development -
Craig Berman,
Vice President - Clinical Development -
Kristin Bedard,
Vice President - Immunobiology -
Carlos Lugo,
Vice President - Quality and CMC Regulatory Operations -
Regina Cheng,
Vice President - Finance, Controller -
Linda Fitzpatrick,
Chief People and Communications Officer -
Edward Albini,
Chief Financial Officer -
Dr. James R. Swartz Ph.D., Sc.D.,
Founder -
Dr. Arturo M. Molina FACP, M.D., MS,
Chief Medical Officer -
Annie J. Chang M.B.A.,
VP of Investor Relations -
Dr. Arturo M. Molina,
Chief Medical Officer -
Dr. Nicki Vasquez Ph.D.,
Chief Portfolio Strategy & Alliance Officer -
David Pauling J.D., M.A.,
Gen. Counsel -
Dr. Shabbir T. Anik,
Chief Technical Operations Officer -
Edward C. Albini,
CFO & Sec. -
Dr. James R. Swartz,
Founder and Member of Scientific Advisory Board -
Nicki Vasquez,
CHIEF PORT. STRAT & ALNCE OFCR -
Corp /De/ Celgene,
-
Michael Jay Ross,
Director -
Partners Viii, L.P.Alta Par...,
-
V Bryan Lawlis,
Director -
Daniel Janney,
Director -
Stephen Worsley,
Chief Business Officer -
& Co., Inc.Merck Sharp & Do...,
-
Venture Partners V Lp Skyli...,
-
V, Llcilsf Iii, Llcinternat...,
-
Jane Chung,
PRESIDENT AND COO -
Venkatesh Srinivasan,
CHIEF TECH OP OFFICER -
Anne Elizabeth Borgman,
CHIEF MEDICAL OFFICER -
Sukhi Jagpal,
-
Hans Peter Gerber,
CHIEF SCIENTIFIC OFFICER -
Heidi Hunter,
-
Jon Marc Wigginton,
-
Barbara Leyman,
Chief Business Dev. Officer